Published by Ministry of Health, Labour and Welfare



Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions Nintedanib Ethanesulfonate

January 12, 2016

Non-proprietary name

Nintedanib Ethanesulfonate

Safety measure

Precautions should be revised in the package insert.

In the Important Precautions section, the following text should be added (underlined parts are revised):

Administration to patients with moderate to severe hepatic function disorder (Child-Pugh B and C) should be avoided unless treatment with this drug is deemed necessary.

> Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>